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PPredicting the Long-Term Effects
of Cardiac Resynchronization Therapy on Mortality
From Baseline Variables and the Early Response
A Report From the CARE-HF
(Cardiac Resynchronization in Heart Failure) Trial
John Cleland, MD, FRCP, FACC,* Nick Freemantle, PHD,† Stefano Ghio, MD,‡ Friedrich Fruhwald, MD,§
Aparna Shankar, PHD,† Monique Marijanowski, PHD, Yves Verboven, Luigi Tavazzi, MD, FESC‡
Hull and Birmingham, United Kingdom; Pavia, Italy; Graz, Austria; and Maastricht, the Netherlands
Objectives This study was designed to investigate whether selected baseline variables and early response markers predict
the effects of cardiac resynchronization therapy (CRT) on long-term mortality.
Background Cardiac resynchronization therapy reduces long-term morbidity and mortality in patients with moderate or severe
heart failure and markers of cardiac dyssynchrony, but not all patients respond to a similar extent.
Methods In the CARE-HF (Cardiac Resynchronization in Heart Failure) study, 813 patients with heart failure and markers
of cardiac dyssynchrony were randomly assigned to receive or not receive CRT in addition to pharmacological
treatment and were followed for a median of 37.6 months. A model including assigned treatment, 15 pre-specified
baseline variables, and 8 markers of response at 3 months was constructed to predict all-cause mortality.
Results On multivariable analysis, plasma concentration of amino terminal pro–brain natriuretic peptide (univariate and multi-
variable model chi-square test: 105.0 and 48.4; both p  0.0001) and severity of mitral regurgitation (chi-square test:
44.0 and 17.9; both p  0.0001) at 3 months, regardless of assigned treatment, were the strongest predictors of
mortality. Ischemic heart disease as the cause of ventricular dysfunction (chi-square test: 34.9 and 7.4; p  0.0001
and p  0.0066), being in New York Heart Association functional class IV (chi-square test: 18.8 and 9.6; p  0.0001
and p  0.0020), or having less interventricular mechanical delay (chi-square test: 29.8 and 8.8; p  0.0001 and
p  0.0029) at baseline all predicted a worse outcome. However, the reduction in mortality in patients assigned to
CRT was similar before (hazard ratio: 0.602; 95% confidence interval: 0.468 to 0.774) and after (hazard ratio: 0.679;
95% confidence interval: 0.494 to 0.914) adjustment for variables measured at baseline and at 3 months.
Conclusions Patients who have more severe mitral regurgitation or persistently elevated amino terminal pro–brain natriuretic
peptide despite treatment for heart failure, including CRT, have a higher mortality. However, patients assigned to
CRT had a lower mortality even after adjusting for variables measured before and 3 months after intervention.
The effect of CRT on mortality cannot be usefully predicted using such information. (CARE-HF CArdiac Resyn-
chronization in Heart Failure; NCT00170300) (J Am Coll Cardiol 2008;52:438–45) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.036t
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entricular (LV) systolic dysfunction and QRS prolongation
n the surface electrocardiogram, cardiac resynchronization
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008, accepted April 3, 2008.herapy (CRT) improves heart function, symptoms, quality
f life, and prognosis (1–4). The clinical response to CRT
s variable, with a continuous spectrum ranging from dra-
atic to disappointing (5), and, so far, its prediction from
aseline variables has met with limited success. A series of
mall observational trials has suggested that cardiac dyssyn-
hrony measured by a variety of echocardiographic tech-
iques might predict the response to CRT (5). For example,
enicka et al. (6) studied 49 patients and concluded that
chocardiographic measures of both intra- and interventric-
lar dyssynchrony predicted improvement in ventricular
unction at 6 months. In a study of 54 patients, Yu et al. (7)
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August 5, 2008:438–45 The CARE-HF Trial: Baseline Variables and Early Responseeported that tissue Doppler imaging predicted improve-
ent in ventricular function at 6 months. Similarly, Bax et
l. (8) studied 80 patients who received CRT using tissue
oppler imaging and reported that the risk of death or
ospitalization with heart failure at 1 year was only 6% in
he 49 patients with intraventricular dyssynchrony 65 ms
ut 50% in those with less marked dyssynchrony. This could
eflect an intrinsically better prognosis in patients with
yssynchrony or a treatment effect. It is not clear whether
he use of short-term improvements in ventricular function
s a surrogate measure of long-term clinical response is
ppropriate, and the few attempts using data from random-
zed controlled trials have, so far, been unable to corroborate
hese findings, although the techniques used might now be
onsidered outmoded (9). Recently, a large prospective,
bservational study (PROSPECT [Predictors of Response
o CRT] trial) was unable to find clinically useful predictors
f the response to CRT over 6 months in terms of clinical
tatus or improvement in LV function (10).
The complex and varied reasons for failure to respond to
RT may be the reason that no robust pre-implantation
arker of therapeutic response to CRT has yet been found.
atient factors may include the severity and type of dyssyn-
hrony, the extent and location of myocardial scarring, and
he severity of and reasons for mitral regurgitation (5,11). It
s also likely that dyssynchrony may develop, and perhaps
isappear, as ventricular dysfunction progresses. The success
f CRT will also depend on the technical success of lead
ositioning and device programming. An alternative ap-
roach to try to assess the role of dyssynchrony in deter-
ining the long-term response to CRT is to investigate
hether the initial response to therapy predicts long-term
utcome, because this simultaneously tests both the patient
ubstrate and the adequacy of implementation of CRT. For
xample, Yu et al. (12) noted that changes in ventricular
unction 3 to 6 months after implantation but not changes
n symptoms predicted long-term survival in an observa-
ional study of 141 patients. Kubanek et al. (13) noted that
hange in natriuretic peptides at 3 months predicted clinical
mprovement at 1 year in a study of 43 patients. However,
esponses to concomitant pharmacological treatment, the
xistence of comorbid conditions, intercurrent events, and
placebo” effects will be important additional determinants
f the apparent clinical response to CRT in observational
rials.
An observational study can address the question of
hether a patient who receives CRT will do well or not, but
annot tell whether the intervention changed the course of
he disease because it lacks a control group. Randomized
rials are required to prove whether an intervention alters
he natural history of disease. A patient who dies 1 year after
eceiving CRT might be considered to have had an excellent
esponse if similar patients in the control group die within
few weeks. Similarly, some patients who appear to respond
ery well to CRT might do just as well without it. 3Clearly, CRT reduces long-
erm mortality. However, if the
ffects of CRT on mortality can
e explained by either baseline
easures of dyssynchrony and/or
he initial response to therapy,
hen being randomized to CRT
hould no longer be associated
ith reduced mortality after ad-
ustment for these factors. Ac-
ordingly, we undertook an anal-
sis to identify whether baseline
ariables and the early response
o CRT could explain its effects
n long-term mortality in the
ARE-HF (Cardiac Resynchro-
ization in Heart Failure) trial.
ethods
he CARE-HF trial was a multicenter, international,
andomized trial that compared the effect of implanting or
ot implanting a CRT device in patients with moderate or
evere symptoms of heart failure despite treatment with loop
iuretics, a left ventricular ejection fraction (LVEF) 35%,
nd markers of cardiac dyssynchrony, in sinus rhythm and
eceiving standard pharmacologic therapy, generally including
ngiotensin-converting enzyme inhibitors, beta-blockers,
nd, for more severe cases, spironolactone. CRT-only de-
ices without a defibrillator function were used. A QRS
uration 120 ms was used as a marker of cardiac dyssyn-
hrony, but patients with QRS durations of 120 to 149 ms
equired at least 2 additional echocardiographic markers of
yssynchrony: an aortic pre-ejection delay 140 ms, an
nterventricular mechanical delay 40 ms, or delayed acti-
ation of the posterolateral LV wall. Patients and investi-
ators were not blinded to treatment allocation, because the
ontrol group did not receive a device. Further details of the
esign, inclusion criteria, baseline clinical and echocardio-
raphic characteristics, and the main results have been
ublished elsewhere (2,3,14).
The steering committee designed the trial. Medtronic
akken Research Center funded the trial and helped to
mplement it. The sponsor had no access to the database and
id not participate in the analysis. All statistical analyses were
erformed by 1 of the authors (N.F.).
The study was approved by the local ethics committee of
ach participating institution and by appropriate national
thics committees. All patients provided written informed
onsent.
mplant procedure and device programming. Multiple
ttempts at device implantation were permitted. Device
mplantation, predominantly of the InSync III Model 8042
Medtronic, Maastricht, the Netherlands), was successful
n the first attempt in 349 patients (85%), on the second in
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
ESVI  end-systolic volume
index
IVMD  interventricular
mechanical delay
LV  left
ventricle/ventricular
LVEF  left ventricular
ejection fraction
MR  mitral regurgitation
NT-proBNP  amino
terminal pro-brain
natriuretic peptide4 (8%), and on the third in 7 (2%). Finally, 390 of 409
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The CARE-HF Trial: Baseline Variables and Early Response August 5, 2008:438–45atients (95%) had a system implanted and activated. Left
entricular leads were from the Attain product line
Medtronic). Standard bipolar right atrial and ventricular
eads were used. Investigators were requested to try to pace
he lateral or posterolateral LV wall via a lateral coronary
ein and to pace the right ventricle at the site with the
ongest delay from LV stimulation to right ventricular
etection, which is usually near the apical septum. Echo-
ardiography was used to identify the end of atrial systole
rom the mitral Doppler signal, which was considered the
ptimal atrioventricular delay. Interventricular delay was set
t 0. Further details on device programming and optimiza-
ion of CRT programming are reported elsewhere (15).
ollow-up and core laboratories. Baseline clinical data,
lectrocardiograms, echocardiograms, and bloods for assess-
ent of renal function and amino terminal pro-brain
atriuretic peptide (NT-proBNP) were collected on the day
f randomization. Key information was sent to an indepen-
ent randomization center prior to assigning patients to the
RT or control group. Device implantation was planned to
ccur within 5 days of randomization. Patients were re-
iewed prior to discharge, at 1 month, at 3 months, every 3
onths for the first year, and then every 6 months. Detailed
ssessments, as at baseline, were repeated at 3 months.
Baseline and follow-up echocardiograms were sent to the
ore echocardiographic laboratory for analysis including LV
nd-systolic and -diastolic volumes, LVEF, and mitral
egurgitation (16). Baseline and follow-up electrocardio-
rams were sent to a core therapy-delivery laboratory.
erum creatinine was measured locally. Plasma was stored at
70°C until the end of the study and then sent to the core
euroendocrine laboratory.
redictive model. The statistical analysis plan of CARE-HF
rawn up before study closure specified 15 variables that
ould be used as covariates in a prognostic model to predict
verall patient outcome and factors that influenced the
linical effects of CRT. These included age, gender, New
ork Heart Association functional class, etiology of LV
ysfunction, use of beta-blockers, systolic blood pressure,*
RS duration,* interventricular mechanical delay (IVMD),*
everity of mitral regurgitation (MR),* left ventricular end-
ystolic volume index (LVESVI),* LVEF,* glomerular fil-
ration rate,* furosemide dose 80 mg/day, NT-proBNP,*
nd body mass index, with allocation to the CRT or the
ontrol group as a 16th variable. For this analysis, we tested
hether variables suggesting a response to CRT between
aseline and 3 months (marked with *) improved the
rognostic accuracy of the model compared with one using
aseline characteristics only. Information on diuretic dose
as not collected at 3 months. Where data were missing at
months, baseline data was substituted for the predicted
-month values when measured to avoid confounding be-
ause of selective loss of information due to death or marked
eterioration in patients’ status. This preserved the integrity
f randomization and the intention-to-treat principle while
ncluding the effects of treatment at 3 months in the model an those subjects still at risk at that time. All-cause mortality
as chosen as the outcome of interest for this analysis as a
obust objective marker of treatment effect. This approach
ests the extent to which baseline characteristics and short-
erm response to CRT, presumably reflecting the amount of
yssynchrony at baseline and the extent to which it was
orrected by treatment, as well as any concomitant adjust-
ent of other therapies predicts outcome. In this model, if
eing assigned to CRT remains a strong predictor of a
etter prognosis, it implies that much of the benefit of CRT
annot be explained by dyssynchrony or its correction, at
east as measured prior to or shortly after implantation.
tatistics. Baseline characteristics were described using
requency or median and interquartile range, as appropriate.
ifferences at baseline between randomized groups were
escribed using the Fisher exact test or Kruskal-Wallis test
or frequency counts or continuous variables. Univariate and
ultivariate analyses predicting all-cause mortality were
eveloped using Cox constant proportional hazards models,
ncluding time-dependent covariates as described. Propor-
ional hazards models were compared (baseline-only and
ime-dependent covariate) using Akaike information crite-
ion, and parsimonious models were preferred unless more
omplex forms (e.g., those with time-dependent covariates)
dded to the model fit. A forward stepwise approach with
ntry to the model set at p  0.1 and the criterion for
emaining in the model set at p  0.05. All analyses were
onducted using SAS 9.1 (SAS Institute, Cary, North
arolina).
esults
total of 813 patients were randomly assigned to receive or
ot receive a CRT device, and 721 were enrolled based on
QRS duration 150 ms alone. By 3 months, 15 patients
ssigned to the control group and 12 patients assigned to
RT had died. Those assigned to CRT had a greater
eduction in QRS, IVMD, LVESVI, MR, and NT-
roBNP (logarithmic values) and a greater increase in
ystolic blood pressure and LVEF compared with the
ontrol group, but changes in glomerular filtration rate were
imilar (Tables 1 and 2).
During a median follow-up of 37.6 (range 26.1 to 52.6)
onths, 154 patients assigned to the control group and 101
ssigned to CRT died. Univariate analysis demonstrated
hat most of the 15 baseline variables, with the exception of
ender, QRS duration, and body mass index, predicted
urvival (Table 3). Greater IVMD at baseline predicted a
etter outcome. The relationship between prognosis and
alues at 3 months for ESVI, LVEF, MR, and NT-
roBNP, regardless of treatment assignment, were stronger,
nd IVMD weaker, compared with baseline values. In the
ultivariable model, baseline variables that independently
redicted shorter survival were ischemic heart disease (p 
.0066) (Fig. 1), less severe IVMD (p  0.0029) (Fig. 2),
nd more severe New York Heart Association functional
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August 5, 2008:438–45 The CARE-HF Trial: Baseline Variables and Early Responselass (p  0.0020) (Table 4, Fig. 3). Further independent
rognostic information was provided by NT-proBNP (p 
.0001) (Fig. 4) and severity of MR (p  0.0001) (Fig. 5)
easured at 3 months. Indeed, NT-proBNP measured at 3
onths was the most powerful prognostic marker (Table 4).
s models may be affected by extreme values, we repeated
nalyses after removing the 5% of patients with the highest
nd lowest levels of NT-proBNP. This did not substantially
hange the result, and neither did rerunning the statistical
odels without using the last observation carried forward
pproach for missing data among eligible patients at 3
onths.
The unadjusted hazard ratio for mortality in patients
ssigned to CRT was 0.60 (95% confidence interval: 0.47 to
.77, p  0.0001). The hazard ratio after adjusting for
ariables measured both at baseline and at 3 months (0.67,
5% confidence interval: 0.49 to 0.91; p  0.0113) was
imilar (Fig. 6). Removing allocation to CRT or control
rom the model reduced the goodness of fit.
Continuous Variables Included in Analysis, at Ba
Table 1 Continuous Variables Included in An
Variable Time Control*
MR Baseline 22.9 (10.8–34.0
3 months 18.8 (10.7–31.3
IVMD Baseline 49.6 (29.6–66.1
3 months 51.2 (28.9–68.8
ESVI Baseline 121.3 (91.8–151.
3 months 116.4 (85.2–149.
LVEF Baseline 24.8 (21.6–29.2
3 months 25.1 (21.7–30.2
Age Baseline 66.2 (59.0–71.7
QRS Baseline 160 (152–180)
3 months 164 (152–180)
NT-proBNP Baseline 1,806 (719–3,949
3 months 1,649 (609–3,704
Systolic BP Baseline 110 (100–125)
3 months 119 (105–130)
GFR Baseline 60.9 (45.6–72.7
3 months 58.8 (47.1–73.7
BMI Baseline 27.0 (23.8–30.3
*Median and interquartile range are shown. †X  no baseline differe
BMI  body mass index; BP  blood pressure; CRT  cardiac resy
filtration rate; IVMD  interventricular mechanical delay; LVEF  left
terminal pro-brain natriuretic peptide.
ategorical Variables Included in Analysis ats line Showing Proportions as a Percentage
Table 2 Categorical Variables Included in Analysis atBaseline Showing Proportions as a Percentage
Variable Control Group CRT
Ischemic heart disease 153 (38.0%) 186 (45.5%)
Treated with beta-blockers 288 (71.3%) 298 (72.9%)
Receiving furosemide 80 mg or equivalent 177 (43.8%) 175 (42.8%)
NYHA functional class IV 27 (6.7%) 23 (5.6%)
Men 293 (72.5%) 304 (74.3%)dRT  cardiac resynchronization therapy; NYHA  New York Heart Association.iscussion
his analysis demonstrates that MR and NT-proBNP
easured 3 months after intervention were powerful inde-
endent predictors of long-term survival in the CARE-HF
tudy. Patients assigned to CRT were more likely to have an
mprovement in MR and a reduction in NT-proBNP (13),
hich suggests that these factors may predict or mediate
ome of the long-term response to this therapy (5,17,18).
owever, the effect of CRT on long-term mortality per-
isted despite adjustment for these and other variables
easured either at baseline or soon after intervention.
ither the study failed to capture some aspects of the early
enefit of CRT or the long-term clinical effects of CRT
annot be accurately predicted from either baseline measures
r the short-term response. These data support the obser-
ation that patients who improve their cardiac function after
eceiving CRT have a better prognosis (12) but, at the same
ime, indicate that this is the mechanism of a relatively small
roportion of the effect of CRT on long-term mortality.
ccordingly, an improvement in cardiac function after
mplanting a CRT device is a welcome sign but an unreli-
ble surrogate for long-term response.
One possible explanation for our findings is that
ardiac dyssynchrony is a much more dynamic phenom-
non than is currently appreciated. The QRS width
ncreases during long-term follow-up (19), but the inci-
ence of dyssynchrony, as opposed to its prevalence, has
ot been reported. Dyssynchrony may have been absent
t baseline but developed during follow-up as part of the
e and 3 Months
s, at Baseline and 3 Months
CRT*
p Value for Difference
Between Groups†
21.3 (11.6–32.9) X
14.1 (7.6–24.8) 0.0002
48.5 (31.7–67.0) X
24.8 (11.7–41.2) 0.0001
116.8 (94.3–146.9) X
94.6 (69.9–123.5) 0.0001
24.6 (21.4–29.0) X
29.3 (24.3–34.8) 0.0001
66.5 (59.5–72.5) X
160 (152–180) X
145 (120–160) 0.0001
1,920 (744–4,288) X
1,112 (482–3,053) 0.016
110 (100–125) X
121 (110–140) 0.0001
59.6 (45.7–73.0) X
59.6 (45.8–77.0) 0.76
26.2 (23.7–29.3) X
re observed between assigned groups.
zation therapy; ESVI  end-systolic volume index; GFR  glomerular
lar ejection fraction; MR  mitral regurgitation; NT-proBNP  aminoselin
alysi
)
)
)
)
3)
0)
)
)
)
)
)
)
)
)
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The CARE-HF Trial: Baseline Variables and Early Response August 5, 2008:438–45ho had it at baseline. Dyssynchrony may be absent at
est but present during exercise or cardiac stress (20,21).
s there is great uncertainty about how, under what
hysiological conditions, and how often dyssynchrony
Figure 1 Outcome in Patients With and Without Ischemic
Heart Disease as the Reported Cause of LVSD
Hazard ratio for patients with ischemic heart disease compared with those
without ischemic heart disease was 1.546 (95% confidence interval 1.129 to
2.118; p  0.0066). LVSD  left ventricular systolic dysfunction.
nivariate Analysis, 1° of Freedom, Showing Relationshipetween Long-Term Mortality and Variables M asured at Baseline
Table 3 Univariate Analysis, 1° of Freedom, Showing RelationsBetween Long-Term Mortality and Variables Measured
Variable Units Parameter Estimate
Age yrs 0.03336 0
Male Yes 0.08430 0
Ischemic Yes 0.74747 0
NYHA functional class IV Yes 0.87025 0
Furosemide 80 mg* Yes 0.72052 0
Beta-blocker Yes 0.42643 0
BMI kg/m2 0.01381 0
Systolic BP mm Hg 0.01578 0
Systolic BP† mm Hg 0.01628 0
MR U‡ 0.02075 0
MR† U‡ 0.02282 0
ESVI ml/m2 0.00251 0
ESVI† ml/m2 0.00446 0
LVEF % 0.03547 0
LVEF† % 0.04676 0
NT-proBNP pg/ml§ 0.49937 0
NT-proBNP† pg/ml§ 0.54872 0
GFR ml/min/m2 0.01687 0
GFR† ml/min/m2 0.01642 0
QRS ms 0.0001411 0
QRS† ms 0.00413 0
IVMD ms 0.01262 0
IVMD† ms 0.00841 0
CRT Yes 0.50739 0
alues that were remeasured are in italics. *Furosemide 80 mg/day was pre-specified in the ana
vailable and baseline value if not. This preserves the integrity of randomization. ‡Calculated as t
quare centimeters. §Logarithmic values used in analysis for brain natriuretic peptide.
CI  confidence interval; QRS  width of QRS complex on the surface electrocardiogram; othehould be measured, the concept of measuring dyssyn-
hrony to predict the response to CRT may be either too
omplex for widespread clinical use or futile.
Figure 2 Outcome in Patients
According to Baseline Duration of IVMD
Values for interventricular mechanical delay (IVMD) of 38 and 61 ms defined
the upper and lower boundaries of the middle tercile. The hazard ratio for
those in the highest versus lowest tercile was 0.473 (95% confidence interval:
0.340 to 0.657; p  0.0001). Tr  tercile.
t 3 Months
aseline and at 3 Months
Chi-Square p Value Hazard Ratio 95% CI
8 24.2327 0.0001 1.034 1.020–1.048
8 0.3404 0.5596 1.088 0.820–1.444
7 34.8759 0.0001 2.112 1.648–2.706
2 18.8172 0.0001 2.388 1.611–3.538
4 32.1688 0.0001 2.055 1.602–2.637
5 10.6860 0.0011 0.653 0.506–0.843
9 1.0640 0.3023 0.986 0.961–1.013
8 16.5315 0.0001 0.984 0.977–0.992
0 20.4542 0.0001 0.984 0.977–0.991
8 22.4824 0.0001 1.021 1.012–1.030
4 44.0400 0.0001 1.023 1.016–1.030
4 4.1181 0.0424 1.003 1.000–1.005
3 15.6954 0.0001 1.004 1.002–1.007
1 9.0175 0.0027 0.965 0.943–0.988
2 20.9506 0.0001 0.954 0.935–0.974
1 77.0084 0.0001 1.648 1.474–1.842
6 104.9740 0.0001 1.731 1.559–1.923
7 21.1283 0.0001 0.983 0.976–0.990
6 22.5253 .0001 0.984 0.977–0.990
1 0.0018 0.9660 1.000 0.994–1.007
9 2.3483 0.1254 1.004 0.999–1.009
1 29.8065 .0001 0.987 0.983–0.992
9 12.3315 0.0004 0.992 0.987–0.996
0 15.6881 .0001 0.602 0.468–0.774
an as indicating high-dose diuretic. †Time-dependent covariate model, with 3-month value when
of the color-flow Doppler regurgitant jet divided by the area of the left atrium in systole, both in
viations as in Tables 1 and 2.and a
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August 5, 2008:438–45 The CARE-HF Trial: Baseline Variables and Early ResponseAmong markers of ventricular dysfunction, only NT-
roBNP retained independent prognostic value, perhaps
ecause it is a more comprehensive single measure of cardiac
unction or because it also reflects renal function, another
owerful prognostic factor in patients with heart failure
22). Indeed, in the CARE-HF trial, the main determinants
f NT-proBNP were age, glomerular filtration rate, LVEF,
R, and, at 3 months, randomization to CRT (23).
espite the relationship between MR and NT-proBNP,
ach retained independent prognostic value in the multiva-
iable model, suggesting that the circulatory stress due to
R is not wholly reflected by plasma concentrations of
T-proBNP. On univariate analysis, LVEF and ESVI
easured at baseline predicted mortality but values mea-
ured at 3 months were much stronger, implying that
mprovement in echocardiographic ventricular function,
hich is more likely to occur in patients receiving effective
RT, indicates that a patient is likely to have a better
utcome. However, improved echocardiographic ventricular
unction was not an independent predictor of outcome. This
s a complex problem. Disease etiology is an important
eterminant of the improvement in ventricular function
Figure 3 Outcome in Patients
According to Baseline NYHA Functional Class
Hazard ratio for those in New York Heart Association (NYHA) functional class
IV versus III was 2.228 (95% confidence interval: 1.341 to 3.701; p  0.0020).
ultivariable Analysis, in Order of Strength of Relationship, Showinha Made an I dependent Contribu io to the Model That Best Pr
Table 4 Multivariable Analysis, in Order of Strength of RelationThat Made an Independent Contribution to the Model
Variable Units Parameter Estimate Standard E
BNP* pg/ml† 0.47914 0.06890
MR* U‡ 0.01877 0.00443
Ischemic Yes 0.43579 0.16049
IVMD ms 0.00859 0.00289
NYHA functional class IV Yes 0.80120 0.25893
CRT Yes 0.39783 0.15700
Time-dependent covariate model, with 3-month value taken when available and baseline valu
Calculated as the area of the color-flow Doppler regurgitant jet divided by the area of the left atr
BNP  brain natriuretic peptide; other abbreviations as in Tables 1 to 3.ith CRT and also of the severity of IVMD but not of the
ffects of CRT on survival (2,24).
The QRS duration has been used as a marker of ventric-
lar dyssynchrony and has predicted a worse prognosis in
pidemiological studies and clinical trials of heart failure
19,25). This has been interpreted as evidence that cardiac
yssynchrony predicts an adverse outcome in patients with
eart failure, but this has not yet been substantiated by
maging studies. The QRS duration is also a marker of the
everity of ventricular dysfunction (26). The inability of
RS duration to predict mortality in this study could reflect
he inclusion only of patients who had a prolonged QRS.
Patients with a longer interventricular mechanical delay
easured by echocardiography had a better prognosis. This
ay reflect a poor prognosis among patients with severe
ight ventricular dysfunction that led to a similar delay in
he time to pulmonary and aortic ejection. On the other
and, greater delay in aortic compared with pulmonary
jection, reflecting greater left intraventricular dyssynchrony
nd inefficiency, might be associated with a better prognosis
Figure 4 Outcome in Patients According to Plasma
Concentration of NT-proBNP Achieved by 3 Months
Plasma concentrations of amino terminal pro–brain natriuretic peptide (NT-
proBNP) of 812 (log: 6.7) and 2,622 (log: 7.8) pg/ml defined the upper and
lower boundaries of the middle tercile. The hazard ratio for those in the highest
versus lowest tercile was 5.682 (95% confidence interval: 3.819 to 8.455;
p  0.0001). Tr  tercile. BNP  brain natriuretic peptide.
ose Variablesed All-C us Mortality
Showing Those Variables
Best Predicted All-Cause Mortality
Chi-Square p Value > Chi-Square Hazard Ratio 95% CI
48.3659 0.0001 1.615 1.411–1.848
17.9233 0.0001 1.019 1.010–1.028
7.3729 0.0066 1.546 1.129–2.118
8.8489 0.0029 0.991 0.986–0.997
9.5747 0.0020 2.228 1.341–3.701
6.4210 0.0113 0.672 0.494–0.914
t. This preserves the integrity of randomization. †Logarithmic values used in analysis for BNP.
systole, both in square centimeters.g Thedict
ship,
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The CARE-HF Trial: Baseline Variables and Early Response August 5, 2008:438–45or several reasons. In a synchronous ventricle, global LVEF
ill represent the sum of segmental myocardial contraction,
ut in a dyssynchronous ventricle, global ejection fraction
ill be an underestimate of total contractile function. The
eason for the abrupt early increase in LVEF with CRT is
resumably due to correction of dyssynchrony, which reveals
he patient’s true underlying global contractile function.
yssynchrony also reflects dysfunctional but viable myocar-
ium, which may be more likely to respond to treatment
uch as beta-blockers (27) and CRT (28). The widely held
iew that patients with extensive dyssynchrony have an
ntrinsically worse prognosis needs to be examined in other
atasets. A previous analysis of the CARE-HF trial showed
hat patients with more marked IVMD had a slightly
reater response to CRT, in terms of death or hospitaliza-
ion for a major cardiovascular event, but that patients with
ess marked IVMD still benefited (29). Other randomized
ontrolled trials have either failed to show that baseline
easures of ventricular dyssynchrony predict benefit with
RT or showed results similar to ours (9,30). It is possible
hat more advanced imaging techniques, including tissue
oppler imaging (5,17) and cardiac magnetic resonance
maging (11), will be able to predict the response of patients
o CRT, but analysis of data from the CARE-HF trial
uggests that observational studies should generally be
nterpreted with caution. Dyssynchrony and CRT may both
e associated with a better outcome and therefore observa-
ional trials may be unable to distinguish between the effects
f disease and of treatment. Recently, the PROSPECT
tudy failed to predict improvement in clinical status or LV
unction, even when sophisticated echocardiographic tech-
iques, including tissue Doppler imaging, were used (10). It
Figure 5 Outcome in Patients According
to Severity of MR Index at 3 Months
Values for mitral regurgitation (MR) index of 11.1 and 24.2 units defined the
upper and lower boundaries of the middle tercile. The hazard ratio for those in
the highest versus lowest tercile was 2.673 (95% confidence interval: 1.881 to
3.799; p  0.0001). Tr  tercile.s also possible that the relationships among outcome, theighly variable patients, and myocardial substrate and the
aried response to CRT of cardiac function, dyssynchrony,
R, and neuroendocrine activation are too complex to be
xplained by our statistical model, which may not have
ncluded important unmeasured variables. However, if this
s the case, it is also unlikely that any simple clinical measure
ill be adequate to predict response.
Among patients assigned to a CRT device in the
ARE-HF trial, those who had persistent moderate or severe
R and/or persistently elevated NT-proBNP at 3 months did
ess well than other patients and might be considered for
dditional interventions. A review of the programming of the
iming of atrioventricular or interventricular stimulation is the
uickest, simplest, and least expensive first option (31). A
eview of pharmacological therapy may identify suboptimal use
f diuretics, angiotensin-converting enzyme inhibitors, beta-
lockers, aldosterone antagonists, and/or angiotensin receptor
lockers or that agents such as nonsteroidal anti-inflammatory
rugs have not been withdrawn. For patients who remain
everely symptomatic despite such measures, palliative care or
dvanced interventions such as an LV assist device or heart
ransplantation might be considered. Whether mitral valve
urgery should be considered in patients with persistent
oderate-to-severe MR is controversial (32).
The CARE-HF trial enrolled only 92 patients (11%) based
n a QRS width of 120 to 149 ms, and these patients had to
ave 2 or more echocardiographic measures of dyssynchrony.
pplying the overall analysis to this subgroup should be done
ith caution because of the additional dyssynchrony inclusion
riteria and because there were few patients or events in this
ubgroup. This analysis cannot draw any conclusions about the
ffects of CRT in patients with QRS 150 ms who did not
ave markers of dyssynchrony.
Figure 6 Mortality According to Assigned Therapy,
Adjusting for Baseline Variables and Initial Response
The adjusted hazard ratio for those assigned to cardiac resynchronization ther-
apy (CRT) was 0.672 (95% confidence interval: 0.494 to 0.914; p  0.0113).
The unadjusted hazard ratio was 0.60 (95% confidence interval: 0.47 to 0.77;
p 0.0001). The curves do not differ appreciably from those derived from
unadjusted data and published previously in Cleland et al. (2,3).
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August 5, 2008:438–45 The CARE-HF Trial: Baseline Variables and Early Responseonclusions
combination of baseline variables and measures of the
arly response to therapy predicted the overall long-term
ortality of patients enrolled in the CARE-HF trial,
egardless of assigned treatment. However, the reduction in
ong-term mortality by CRT was poorly explained by
aseline measures of cardiac dyssynchrony or the short-term
esponse to biventricular pacing. These data suggest that
atients should be selected for atriobiventricular pacing
sing the entry criteria of successful randomized controlled
rials. It is not clear that identification of dyssynchrony on a
esting echocardiogram is an appropriate way to choose
atients for CRT, especially if their QRS is 150 ms.
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